Literature DB >> 27759570

Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression.

Mariusz Papp1, Piotr Gruca, Magdalena Lason-Tyburkiewicz, Paul Willner.   

Abstract

Ketamine is the prototype of a new generation of antidepressant drugs, which is reported in clinical studies to be effective in treatment-resistant patients, with an effect that appears within hours and lasts for a few days. Chronic mild stress (CMS) is a well-established and widely used animal model of depression, in which anhedonia, anxiogenesis and cognitive dysfunction can be observed reliably. Studies using acute or brief ketamine treatment following withdrawal from CMS have replicated the clinical finding of a rapid onset of antidepressant action. However, there have been no CMS studies of chronic daily ketamine treatment or continued stress following ketamine treatment, which would have greater translational potential in relation to the long-term maintenance of antidepressant effects. Wistar rats were drug treated following an initial 2 weeks of CMS exposure, which continued alongside daily drug treatment. A first experiment tested a range of chronic (5 weeks) ketamine doses (5-30 mg/kg); a second compared the effects of subacute (3-5 days) and chronic (5 weeks) treatment. CMS-induced anhedonic, anxiogenic and dyscognitive effects, as measured, respectively, by decreased sucrose intake, avoidance of open arms in the elevated plus maze and loss of discrimination in the novel object recognition test. A sustained antidepressant-like effect of ketamine in the sucrose intake test was observed in both experiments, with an onset at around 1 week, faster than imipramine, and an optimum dose of 10 mg/kg. Anxiogenic and dyscognitive effects of CMS, in the elevated plus maze and novel object recognition test, respectively, were fully reversed by both subacute and chronic ketamine treatment. Daily treatment with ketamine in the CMS model causes sustained long-term antidepressant, anxiolytic and procognitive effects. The demonstration of a procognitive effect of ketamine may have particular translational value.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27759570     DOI: 10.1097/FBP.0000000000000259

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  14 in total

1.  Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.

Authors:  Samuel T Wilkinson; DaShaun Wright; Madonna K Fasula; Lisa Fenton; Matthew Griepp; Robert B Ostroff; Gerard Sanacora
Journal:  Psychother Psychosom       Date:  2017-05-11       Impact factor: 17.659

Review 2.  Ketamine and pharmacological imaging: use of functional magnetic resonance imaging to evaluate mechanisms of action.

Authors:  Eric A Maltbie; Gopinath S Kaundinya; Leonard L Howell
Journal:  Behav Pharmacol       Date:  2017-12       Impact factor: 2.293

Review 3.  The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits.

Authors:  Danica Nogo; Ashitija K Jasrai; Haeun Kim; Flora Nasri; Felicia Ceban; Leanna M W Lui; Joshua D Rosenblat; Maj Vinberg; Roger Ho; Roger S McIntyre
Journal:  Psychopharmacology (Berl)       Date:  2022-03-15       Impact factor: 4.530

4.  Peptide LCGA-17 Attenuates Behavioral and Neurochemical Deficits in Rodent Models of PTSD and Depression.

Authors:  Anton V Malyshev; Iuliia A Sukhanova; Valeria M Ushakova; Yana A Zorkina; Olga V Abramova; Anna Y Morozova; Eugene A Zubkov; Nikita A Mitkin; Vsevolod V Pavshintsev; Igor I Doronin; Vasilina R Gedzun; Gennady A Babkin; Sergio A Sanchez; Miah D Baker; Colin N Haile
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-12

Review 5.  The chronic mild stress (CMS) model of depression: History, evaluation and usage.

Authors:  Paul Willner
Journal:  Neurobiol Stress       Date:  2016-08-24

6.  Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents.

Authors:  Piotr Popik; Małgorzata Hołuj; Tomasz Kos; Gabriel Nowak; Tadeusz Librowski; Kinga Sałat
Journal:  Neurotox Res       Date:  2017-06-02       Impact factor: 3.911

7.  Sex-Dependent Ketamine Addiction-Like Behavior Profile Following Exposure to Chronic Mild Stress.

Authors:  Katherine N Wright; Devin P Hagarty; Caroline E Strong; Kristin J Schoepfer; Mohamed Kabbaj
Journal:  Chronic Stress (Thousand Oaks)       Date:  2019-02-27

8.  Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine.

Authors:  Paolo Tornese; Nathalie Sala; Daniela Bonini; Tiziana Bonifacino; Luca La Via; Marco Milanese; Giulia Treccani; Mara Seguini; Alessandro Ieraci; Jessica Mingardi; Jens R Nyengaard; Stefano Calza; Giambattista Bonanno; Gregers Wegener; Alessandro Barbon; Maurizio Popoli; Laura Musazzi
Journal:  Neurobiol Stress       Date:  2019-04-02

9.  Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment`.

Authors:  Mariusz Papp; Piotr Gruca; Magdalena Lason-Tyburkiewicz; Ewa Litwa; Monika Niemczyk; Katarzyna Tota-Glowczyk; Paul Willner
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

Review 10.  Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.

Authors:  Bashkim Kadriu; Laura Musazzi; Ioline D Henter; Morgan Graves; Maurizio Popoli; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.